(90 days)
Not Found
No
The summary describes standard image processing techniques (attenuation correction, iterative reconstruction) and does not mention AI, ML, or related concepts.
No.
The device is an imaging system designed to acquire and process SPECT images for diagnostic purposes, not to treat a disease or condition.
Yes
This device is a gamma camera for SPECT imaging, which is a medical imaging technique used to diagnose various conditions, particularly cardiac studies. It generates images and data that are reviewed by physicians to make diagnostic decisions.
No
The device description explicitly states it is a "gamma camera for Single Photon Emission Computed Tomography (SPECT) integrated with an attenuation device consisting of an x-ray generator," and that it "consists of an x-ray generator integrated with the previously cleared Cardius 3 XPO triple head SPECT system." This indicates significant hardware components beyond just software.
Based on the provided text, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
- Device Function: The Cardius 3 X-ACT Imaging System is a medical imaging device that uses gamma rays and x-rays to create images of the heart. It works by detecting radiation emitted from a radioactive tracer administered to the patient.
- Lack of Sample Analysis: The device does not analyze biological samples taken from the patient. It directly images the patient's body.
Therefore, the Cardius 3 X-ACT Imaging System falls under the category of medical imaging devices, not in vitro diagnostics.
N/A
Intended Use / Indications for Use
The Cardius 3 X-ACT Imaging System is a gamma camera for Single Photon Emission Computed Tomography (SPECT) integrated with an attenuation device consisting of an x-ray generator. The Cardius 3 X-ACT Imaging System is intended for use in the generation of cardiac studies, including planar and SPBCT studies, in nuclear medicine applications. Cardius 3 X-ACT produces non-attenuation corrected SPECT Images and attenuation corrected SPECT images with x-ray transmission data that may also be corrected for scatter.
Product codes (comma separated list FDA assigned to the subject device)
KPS
Device Description
The Cardius® 3 X-ACT Imaging system is a gamma camera for the acquisition and processing of Single Photon Emission Computed Tomography (SPECT) as well as correcting attenuation artifacts associated with these Emission studies. The device consists of an x-ray generator integrated with the previously cleared Cardius 3 XPO triple head SPECT system to provide attenuation correction functionality. The attenuation correction functionality will be included with the Cardius 3 X-ACT imaging system, or offered as an accessory for previously purchased Cardius 3 XPO systems that are configured to accept the attenuation correction functionality.
The Cardius 3 X-ACT Imaging system is designed to provide extended imaging functionality relative to the current Cardius XPO series imagers. A typical patient study comprises an emission (SPECT) study followed by a transmission study. The SPECT study is acquired using the similar system hardware and software technology as a Cardius-3 XPO imaging system. For the transmission study, the low dose x-ray generator is used to produce an attenuation map that is used for attenuation correction (AC) of the emission data. An iterative reconstruction technique then uses the attenuation map and the SPECT data as input, and the AC and non-AC reconstructed volumes are saved in the database for physician review. The attenuation correction data provided is additional information that may be reviewed by the interpreter. The original SPECT data remains available to the interpreter.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Single Photon Emission Computed Tomography (SPECT), X-ray transmission
Anatomical Site
Cardiac
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Verification and Validation tests were conducted to demonstrate the Cardius 3 X-ACT functioned as per its specifications. Bench testing was done per guidelines for radiation measurements. All tests passed with the actual results substantially matching the expected results. The testing shows Cardius 3 X-ACT meets the design specifications, which are similar to the predicate device functional specifications. Digirad internal testing and clinical images obtained with the Cardius 3 X-ACT imaging system have demonstrated equivalent efficacy to the predicate devices, and did not raise new questions regarding safety and effectiveness.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 892.1200 Emission computed tomography system.
(a)
Identification. An emission computed tomography system is a device intended to detect the location and distribution of gamma ray- and positron-emitting radionuclides in the body and produce cross-sectional images through computer reconstruction of the data. This generic type of device may include signal analysis and display equipment, patient and equipment supports, radionuclide anatomical markers, component parts, and accessories.(b)
Classification. Class II.
0
9 2009 MAR
Appendix 2: 510(k) Summary
A. Sponsor
Digirad Corporation 13950 Stowe Drive Poway, California 92064 Contact Person: Joel Tuckey Tel: (858) 726-1527 Fax: (858) 726-1700
B. Date Prepared: December 8, 2008
C. Device Name
| Trade Name: | Cardius 3 X-ACT Imaging System |
|---|---|
| Common Name: | Gamma Camera System |
| Classification Name: | System, Emission Tomography |
| Device Class: | 21CFR 892.1200, Class II |
| Product Code: | KPS |
D. Cleared/Predicate Devices
The Cardius 3 X-ACT Imaging System is substantially equivalent to the following cleared devices:
BrightView VCT Imaging System cleared April 11, 2008 under K080927 for Philips (1) Medical Systems
Cardius 3 XPO Imaging System cleared March 23, 2007 under K070542, and (2) September 12, 2008 under K082368 for Digirad Corporation.
E. Device Description
The Cardius® 3 X-ACT Imaging system is a gamma camera for the acquisition and processing of Single Photon Emission Computed Tomography (SPECT) as well as correcting attenuation artifacts associated with these Emission studies. The device consists of an x-ray generator integrated with the previously cleared Cardius 3 XPO triple head SPECT system to provide attenuation correction functionality. The attenuation correction functionality will be included with the Cardius 3 X-ACT imaging system, or offered as an accessory for previously purchased Cardius 3 XPO systems that are configured to accept the attenuation correction functionality.
The Cardius 3 X-ACT Imaging system is designed to provide extended imaging functionality relative to the current Cardius XPO series imagers. A typical patient study comprises an emission (SPECT) study followed by a transmission study. The SPECT study is acquired using the similar system hardware and software technology as a Cardius-3 XPO imaging system. For the transmission study, the low dose x-ray generator is used to produce an attenuation map that is used for attenuation correction (AC) of the emission data. An iterative reconstruction technique then uses the attenuation map and the SPECT data as input, and the
1
AC and non-AC reconstructed volumes are saved in the database for physician review. The attenuation correction data provided is additional information that may be reviewed by the interpreter. The original SPECT data remains available to the interpreter.
F. Intended Use
The intended use is the same as the predicate devices. The Cardius 3 X-ACT Imaging System is a gamma camera for Single Photon Emission Computed Tomography (SPECT) integrated with an attenuation device consisting of an x-ray generator. Cardius 3 X-ACT produces non-attenuation corrected SPECT Images and attenuation corrected SPECT images with x-ray transmission data that may also be corrected for scatter.
ে Technology
The Philips Medical Systems BrightView VCT imaging system (K080927) and Digirad's Cardius 3 XPO (K070542 and K082368) predicate devices have similar technology (gamma camera for SPECT imaging and x-ray based attenuation correction), and the same intended use as the Cardius 3 X-ACT imaging system. In Cardius 3 X-ACT, Digirad's internally developed proprietary algorithms are implemented using software technology. A low-dose xray generator is used for attenuation correction. Digirad's solid state detectors are used to acquire both emission (SPECT) and transmission scans. The transmission and emission scans share the same imaging plane. The patient sits upright in a chair that rotates to acquire both emission and transmission scans.
H. Testing
Verification and Validation tests were conducted to demonstrate the Cardius 3 X-ACT functioned as per its specifications. Bench testing was done per guidelines for radiation measurements. All tests passed with the actual results substantially matching the expected results. The testing shows Cardius 3 X-ACT meets the design specifications, which are similar to the predicate device functional specifications. Digirad internal testing and clinical images obtained with the Cardius 3 X-ACT imaging system have demonstrated equivalent efficacy to the predicate devices, and did not raise new questions regarding safety and effectiveness.
I. Conclusion
Testing results demonstrate that the Cardius 3 XPO Imaging System meets the specifications and is substantially equivalent to the predicate devices, based on comparisons of intended use and technology, and overall system performance.
2
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES (USA)" arranged around the perimeter. Inside the circle is a stylized graphic of an eagle or bird-like figure with three horizontal lines extending from its body, representing the department's mission to protect the health of all Americans and provide essential human services.
Public Health Service
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
9 2009 MAR
Mr. Joel Tuckey Vice President Quality Digirad® Corporation 13950 Stowe Drive POWAY CA 92064-8803
Re: K083649
Trade/Device Name: Cardius 3 X-ACT Imaging System Regulation Number: 21 CFR §892.1200 Regulation Name: Emission computed tomography system Regulatory Class: II Product Code: KPS Dated: March 3, 2009 Received: March 4, 2009
Dear Mr. Tuckey:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
3
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801; good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding os substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter.
| 21 CFR 876.xxx | (Gastroenterology/Renal/Urology) | (240) 276-0115 |
|---|---|---|
| 21 CFR 884.xxx | (Obstetrics/Gynecology) | (240) 276-0115 |
| 21 CFR 892.xxx | (Radiology) | (240) 276-0120 |
| Other | (240) 276-0100 |
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometrics' (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufactures, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrb/industry.suppor/index.html.
Sincerely yours,
Janine M. Morris
Acting Director, Division of Reproductive, Abdominal, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
Page 1 of 1
Indications for Use 510(k) Number (if known): K083649 Device Name: Cardius 3 X-ACT Imaging System
Indications for Use:
The Cardius 3 X-ACT Imaging System is a gamma camera for Single Photon Emission Computed Tomography (SPECT) integrated with an attenuation device consisting of an x-ray generator. The Cardius 3 X-ACT Imaging System is intended for use in the generation of cardiac studies, including planar and SPBCT studies, in nuclear medicine applications. Cardius 3 X-ACT produces non-attenuation corrected SPECT Images and attenuation corrected SPECT images with x-ray transmission data that may also be corrected for scatter.
Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Aonchhang
(Division Sign-Off) (Division Sign-On)
Division of Reproductive, Abdominal, and Radiological Device 510(k) Number _